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Introduction
The sixth Expedition Inspiration conference was held
from February 28 to March 3, 2002 at The Sun Valley
Lodge. While there are other conferences that con-
centrate on a particular facet of breast cancer, the
design and goals of this conference are unusual. In
order to maximize interaction of investigators and
clinicians the meetings are small, invited, and private.
The participants include both senior and junior phy-
sicians and scientists involved in clinical and basic
research as well as clinical practice. Some participants
have been at previous Expedition Inspiration meet-
ings while others are new. The meetings serve four
purposes:
1. Active discussion among participants who do not
usually interact.
2. Develop consensus as to the state of our knowledge
on particular aspects of breast cancer to simulate
future studies.
3. Develop collaborative projects among the meeting
participants.
4. Foster new investigations by participants as well as
others.
This year’s conference emphasized the real and
potential clinical applications of some of the molecu-
lar aspects of breast cancer. Markers of prognosis
and tumor progression were considered as they affect
management. Hormones and their cognate receptors,
cytokines, as well as specific signal transduction path-
ways were all considered for the development of
more specific breast cancer treatment. The consensus
statement from the meeting follows.
Prognostic and predictive markers
There is general agreement that many women with
primary breast cancer receive unnecessary treatment
following surgery. For example, large meta analyses of
randomized trials, and several series of uncontrolled,
retrospective studies indicate that approximately 70%
of women whose tumor has not spread to the axil-
lary lymph nodes are alive and disease-free 10 years
after surgery with no additional systemic chemother-
apy or endocrine therapy. Unfortunately, the currently
available prognostic factors, either alone or in com-
bination, cannot accurately identify this large subset
of patients who will derive very little benefit from ad-
ditional adjuvant therapy. Given the proven clinical
benefits of adjuvant therapy, even among subsets of
patients with node-negative disease, it is increasingly
difficult to conduct prospective clinical trials that in-
clude untreated control groups. Therefore, there is a
need to retrospectively identify and collect tumor and
non-malignant host tissue samples from large series
of well-characterized patients who did not receive ad-
juvant therapy and for whom long-term follow-up is
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available. These types of tissues can be used to cre-
ate molecular fingerprints of individual cancers as
well as host factors using emerging molecular biol-
ogy tools, which could help identify new panels of
prognostic biomarkers. The combination of anatomic,
biologic and molecular features could provide a more
accurate assessment of the likely clinical course of
an individual breast cancer, and help determine the
most appropriate treatment strategy for an individual
patient.
An area of concern that needs additional attention
has arisen from our desire to improve the accuracy
of existing breast cancer prognostic and predictive
parameters. Retrospective studies of archived surgical
specimens from previously staged and treated breast
cancer patients now indicate that even the best of
pathologists, using standard histologic techniques, are
unable to discern millimeter-sized breast tumor nodal
deposits in up to 20–30% of patients originally thought
to have node-negative disease. This possible error
in pathologic staging of node-negative breast cancers
may account for the generally observed ∼20% metas-
tatic relapse rate of patients with early-stage disease
and needs to be further evaluated.
New therapies for breast cancer that target specific
molecular pathways are currently being developed.
An important use of biomarkers is the determination
that the pathway is active and functional in a spe-
cific patient before therapy is given. A second use
is to determine that the therapy has actually altered
the pathway and has provided clinical benefit to the
patient. This class of predictive biomarkers is grow-
ing rapidly, and new types of clinical trials will be
required to truly validate their clinical utility. There
is a significant need to standardize many assay meth-
odologies for measuring biomarker levels. The de-
velopment of immunoreagents suitable for use on
paraffin-archived tissues and able to semi-quantitate
ER/PR and HER2/ErbB2 receptor expression have
clearly pointed to the need for more standardized
and validated assay procedures to accurately assess
any given biomarker. In particular, the commercial
availability and community use of many different
but unvalidated antibodies currently employed in PR
and HER2/ErbB2 immunohistochemical assays have
led to widespread discordances between the assay
results and inaccurate biomarker scoring when as-
sessed against identical test samples. Since predict-
ive biomarkers are often used to identify patients
eligible to receive selective biomarker-targeted thera-
peutics (e.g., endocrine therapy, or treatment with the
anti-HER2/ErbB2 antibody trastuzumab), inaccurate
biomarker assays result in unacceptable personal and
economic consequences. Assay development, stand-
ardization and validation should parallel the develop-
ment and evaluation of new therapies, so those patients
who will or will not respond to specific targeted ther-
apies can be accurately identified. Appropriately, this
particular issue is now receiving increased regulatory
(e.g., FDA) attention.
Somewhat more distant on the translational re-
search horizon are encouraging reports from sev-
eral research groups who are employing thousands
of newly available gene sequences from the Human
Genome Project coupled with novel bioengineering
advances that allow simultaneous quantification of the
expression of all these genes from a given breast tumor
on a single microscope slide-based assay. Such mo-
lecular profiling of breast cancers by gene expression
microarrays appears to be confirming the existence of
many hitherto unrecognized subsets of breast tumors;
from these exciting results we expect to establish more
accurate signatures of those breast tumors destined to
metastasize and those most likely to respond to our
best therapeutics.
Steroid receptors
Human mammary epithelial cells and many breast
carcinomas express one or both of the two estrogen
receptors, ERα and ERβ. The single most import-
ant marker of estrogen sensitivity and response to
tamoxifen therapy in breast cancer is the presence of
ERα in tumor cells. ERα is also considered a signi-
ficant target for breast cancer prevention by selective
estrogen receptor modulators (SERMs) like tamox-
ifen and raloxifene, as demonstrated by the NSABP
P1 and MORE trials. Both ER subtypes are presum-
ably the targets of aromatase inhibitors, which have
been shown to be at least as effective as tamoxifen
for preventing or delaying recurrent hormone depend-
ent disease. In addition, recent data suggest that the
frequent occurrence of a somatic point mutation in
ERα (K303R) that increases its sensitivity to estrogens
is significantly associated both with breast hyperplasia
and metastatic diseases. Thus, ERα remains a major
target for breast cancer prevention and therapy and
ERβ is a potential target.
The expression, function and importance of ERβ
in normal breast epithelium and in breast cancer are
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unclear at the present time. Estrogens and SERMs reg-
ulate diverse cellular activites via one or both of the
two ER subtypes (ERα and ERβ) in hormone respon-
sive tissues and cancers. Liganded ERs can interact
with a complex mix of coactivators, corepressors and
other signaling molecules that differ in expression and
importance from tissue to tissue. In addition, differ-
ent SERMs may alter the affinity and/or selectivity
of one or both ERs for these coregulators, allowing
for tissue-selective responses. There is also evidence
that the two ER subtypes can have different actions
in the same tissue and that they can interact with
each other, which may result in complex responses
to a given SERM. Recent ERα and ERβ structure in-
formation provides a partial molecular explanation for
estrogen agonism and antagonism. The crystal struc-
tures of ERα and ERβ ligand binding domains (LBDs)
complexed with a number of SERMs, ranging from
full agonists (estradiol and diethylstilbestrol), to par-
tial agonists (genistein), to mixed agonists/antagonists
(raloxifene and tamoxifen), to complete antagonists
(faslodex). This information has helped define and
predict some of the properties and behaviors one
might expect from different SERMs. However, our
knowledge of the underlying mechanisms is far from
complete. For example, dysregulation of the ERα co-
activator AIB1 may result in over-stimulation of ERα
in some breast cancers. Also, it is likely that rapid,
nongenomic actions of SERM-ER complexes are im-
portant and largely unstudied mechanisms by which
SERMs regulate proliferation, apoptosis or other cell-
specific responses to SERMs. Thus, the current chal-
lenges in this area are: (1) understanding the molecular
mechanisms by which SERMs elicit tissue-selective
agonist or antagonist responses via one or both ER
subtypes, and (2) understanding the roles of ERα
and ERβ expression and modification in breast cancer
genesis and progression to hormone independence.
It is thought that most invasive breast cancers de-
velop over may years from premalignant lesions. Only
a few of these benign lesions, such as usual ductal
hyperplasia or atypical hyperplasia, appear to have
significant premalignant potential. Unfortunately, our
understanding of the underlying biology and clinical
course of these lesions is incomplete. Based on epi-
demiological evidence, breast cancer evolution has
been proposed in which normal ductal epithelium
evolves to usual and atypical hyperplasia, to car-
cinoma in situ, to invasive, and finally to metastatic
cancer. Hyperplasias are considered weak risk factors
for developing invasive breast cancer (approximately
2–5 fold), with increasing risks seen for carcinoma in
situ (10-fold). It has also been proposed that many of
these premalignant lesions never progress to invasive
cancer, so their progression can be viewed as non-
obligatory, presumably requiring the accumulation of
additional genetic events to facilitate eventual tumor
development.
How might these additional genetic events accu-
mulate? One key factor thought to play a role in both
the development and progression of these early lesions
is estrogen. Estrogens are important for regulating
the proliferation of breast cancer and premalignant le-
sions. Estrogens affect cellular processes by binding
to their cognate receptors, ERα and ERβ, and func-
tion as transcription factors to mediate the mitogenic
effects of estrogen. One hallmark of premalignant
lesions is an increase in ERα expression. The rela-
tive overexpression of ERα early in breast cancer
evolution could conceivably influence its course via
inappropriate proliferation, and potential accumula-
tion of genetic alterations. Thus, we hypothesize that
inappropriate overexpression of wild-type ERα or the
emergence of a mutated ERα driving proliferation
could be early molecular events in the evolution of
premalignant breast disease. Furthermore, since the
ER status of breast cancer metastases usually cor-
relates with the ER status of the primary tumor, an
emerging area of research is focused on understanding
the role that ER may play in the metastatic progression
of breast cancers. It is conceivable that early in breast
cancer progression, ER-negativity could be considered
a virulence factor, but later in the disease dissemi-
nation, ER-positive tumors, especially those with a
mutant form of the ERα(K303R), may play another
role in the metastagenicity of breast cancer. Studies
examining these ‘new’ roles for ER in breast cancer
are warranted.
Therefore additional molecular, structural and
functional information is needed to improve our
knowledge of how ERα and ERβ mediate individual
and collective responses to SERMs, especially in con-
cert with intersecting growth factor pathways and with
coactivators and corepressors that may be inappropri-
ately up- or down-regulated. More information is also
needed about the expression and roles of ERα, ERβ
and any mutant forms of these receptors in normal
breast epithelium and in progressive breast disease.
The development of novel SERMs that can elicit
ER subtype-selective responses, both agonisitic and
antagonistic, should also be an important goal for
therapeutic or preventive intervention.
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Potential clinical application of glucocorticoid
receptor activation in breast cancer
The role of nuclear hormone receptors in the develop-
ment of breast cancers has been the subject of intense
interest. The majority of studies have focused on the
function and expression of estrogen, progesterone and
to a lesser extent, prolactin receptors in mammary
gland development and function. Despite the ubiqui-
tous nature of glucocorticoid receptor (GR) expression
in normal and malignant mammary epithelium, the
GR has received relatively little consideration as a po-
tential signaling pathway in breast cancer. However,
recent data from transgenic mice and cell culture ex-
periments using human malignant and non-malignant
breast epithelium point to an important role for the
GR in both mammary gland development and survival
signaling of breast epithelial cells.
Using transgenic mice models that substitute a
mutant GR receptor for the wild type receptor, it has
been shown that a lack of GR DNA binding func-
tion impairs the ductal development of the mammary
gland in virgin females, although the mechanism (e.g.,
a proliferative versus apoptotic defect) is not estab-
lished. The GR is also known to be required for
normal lactation in adult mice, however, the GR’s
DNA binding function does not appear to be required
for this function. Recently, investigators from sev-
eral laboratories have demonstrated a potent in vitro
survival effect from GR activation in mammary epi-
thelial cells subjected to growth factor deprivation.
The role of glucocorticoid in inhibiting paclitaxel-
mediated cell death in breast cancer cell lines has
also been recently demonstrated. Together, these ob-
servations raise the interesting possibility that GR
activation may have an important anti-apoptotic role in
mammary epithelial cell biology. In view of the phar-
macologic doses of glucocorticoid that are routinely
administered prior to chemotherapy in breast cancer
patients, as well as the potentially high local levels of
endogenous corticosteroids produced by adipose tis-
sue in the human breast, the role of GR activation in
breast cancer signaling should be studied further. Such
studies should encompass both a basic laboratory ap-
proach as well as attention to the potential effects that
glucocorticoid therapy may have on the effectiveness
of cytotoxic treatment in breast cancer. If GR ac-
tivation is confirmed to play an important role in
breast epithelial survival signaling GR, antagonists
may eventually be explored as a novel therapeutic
modality for breast cancer.
Targeted therapy of breast cancer
It is increasingly apparent that the term ‘breast can-
cer’ describes a population of diseases with elements
of functional commonality and interrelated but dis-
tinct molecular genotypes and phenotypes. Patterns of
hormone and growth factor receptor polymorphisms,
expression, overexpression and mutation define some
of these phenotypes, and help to define new thera-
peutic targets. In recent years, much interest has
focused on the epidermal growth factor receptor fam-
ily, with particular emphasis on HER2/Erb2/neu as
a therapeutic target. It is likely that important new
treatment options will emerge as new cell surface-
associated receptor targets are identified and validated.
However, multiple lines of evidence now indicate
that the net effect of perturbations in growth factor
receptor-mediated signaling is to inhibit the activa-
tion of key intracellular kinases such as AKT. These
findings suggest two potentially complementary ap-
proaches to the therapeutic inhibition of breast cancer
cell signaling. In the first instance, the function of the
downstream kinase can be directly inhibited; this will
have important therapeutic implications if this can be
accomplished with functional selectivity for malignant
as opposed to normal cells. In the second scenario,
the direct inhibition of the targeted kinase will be
unacceptably toxic to normal cells. If so, the only
way to achieve therapeutic inhibition of that kinase
will be to selectively inhibit the cancer-related sig-
naling elements that influence the phosphorylation of
that kinase. Defined combinations of upstream or as-
sociated pathway inhibitors tailored to the molecular
phenotype of a particular cancer can be employed to
create an indirect or ‘summation inhibition effect’ of
the targeted downstream kinase. Thus, the targeted
kinase is selectively inhibited in cancer cells, but in
fewer normal cell types. Irrespective of the means
by which targeted therapy exerts its anti-tumor ef-
fects, the successful implementation of this evolving
approach is likely to include combination with classic
cytotoxic chemotherapy agents.
The development of herbals and other natural
products as anti-cancer agent
There is a need for agents with greater efficacy and
decreased toxicity for the treatment and prevention of
breast cancer. The majority of agents developed to date
are either natural products, such as vincas and taxanes,
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antimetabolites or alkylators. Most of these agents
have either been found by empiric screening of natural
products or synthesized chemicals. Recently, with the
identification of potentially more specific molecular
targets for therapy, a few agents have been developed
rationally, including trastuzumab and several novel
SERMs. It seems clear that with the identification and
validation of more targets for therapy, the need for
agents that specifically block or inhibit the targets or
pathways of interest will become even more important.
Many patients seeking additional gains have used
a wide variety of alternative therapies including
various nutritional supplements and herbal remedies.
In some cultures, the latter are considered a legitimate
alternative to more traditional Western pharmaceuti-
cals. Unfortunately, the development of these herbal
remedies as validated means of treating cancer has
been hampered for several reasons. First, most
of hese herbal remedies exist as inexact formulations
of multiple components, each of which may, in and of
itself, be an impure extract. Second, few, if any, such
herbals have been subjected to rigorous evaluation us-
ing credible trial designs. Third, the mechanisms of
action for herbal agents are rarely known. Possibly,
the greater the difficulty in establishing an intellec-
tual property position for some of these agents may
have also slowed their development by pharmaceutical
companies. Nonetheless, there is widespread belief
amongst patients, as well as healthcare profession-
als, that significant activities are to be found buried
in these complicated mixtures of agents.
We believe that this area of investigation needs
substantially more attention. The individual chem-
ical moieties contained within these mixtures need
to be identified and structurally analyzed. Modern
pharmacophore methodologies suggest that uniquely
defined ingredients contained within these herbal
remedies can be ‘matched’ to specific targets whose
structures have been solved by crystallography or
NMR means. It is also critical that defined chem-
icals within such herbal teas be used in tradi-
tional empiric screens employed by the NCI as
well as pharmaceutical companies. Finally, it is
essential that agents which show in vitro activ-
ity be evaluated either in formal, well-designed
clinical trials of clinical efficacy or explored by
approaches using surrogate endpoints of response,
so that evidence of efficacy can be obtained
efficiently.
Progression and prognosis in breast cancer
Cancer is a disease involving dynamic changes in
the genome. Multiple steps occur in the progression
from a normal cell to the malignant phenotype, and
further progression and changes occur even in an
already malignant cell and the clinically apparent tu-
mor. These changes account for the heterogeneity in
the clinical presentation of cancer, and the differences
in outcome in seemingly uniform patient populations.
The understanding of the molecular characteristics of
this progression may allow a better individualizing of
therapy.
Multiple genotyping changes are needed to de-
velop traits that are necessary for cancer progression.
Epigenetic mechanisms, as well as extracellular sig-
nals, contribute to tumor phenotype. Tumors may
undergo different permutations of genetic events to
arrive at the necessary phenotype. Genotype identi-
fies the malignant traits but the mutational paths to
a specific phenotype are varied and redundant. Con-
vergent evolution requires that only certain essential
phenotypes be acquired, hence evolutionary selec-
tion determines the dominant mutational pathways and
resulting phenotype.
Expression of molecular markers of metastatic
progression can be determined in human breast
cancer specimens obtained at surgery, and they can be
correlated with the known clinical outcome. The im-
portant phenotypes necessary for cancer progression
are growth, neovascularization, decreased homophilic
adhesion, motility, invasion and metastasis. All these
traits can be determined on tissue. Early markers are
likely those that are expressed in the majority of
tumors and these are not contributory to prognosis be-
cause they would be present in all cases. Angiogenesis
and expression or urokinase plasminogen activator, for
example, are high in most node-negative breast can-
cers and therefore have little overall prognostic value.
In contrast, loss of nm23, abnormal p53, increase in
MMP-2 and decrease in E-cadherin which occur in
progressively smaller proportions of node-negative
breast cancers at diagnosis and represent phenotypes
of more advanced disease progression are therefore
expected to have greater prognostic impact.
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